Pulmonary Fibrosis Clinical Trials

Jasper : 1199.33.01012 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Phoenix : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Phoenix : 1199.33.01003 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Phoenix : Arizona Pulmonary Specialists

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl

Scottsdale : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Tucson : University of Arizona

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl

Los Angeles : Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan

Los Angeles : David Geffen School of Medicine UCLA

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan

Los Angeles : David Geffen School of Medicine UCLA

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil

Los Angeles : VA Greater LA Health Care System-UCLA

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl

Los Angeles : David Geffen School of Medicine, UCLA

Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension

View More »

Rancho Mirage : Advances in Medicine

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Sacramento : University of California- Davis Medical Center

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl

San Francisco : Investigational Site Number 840008

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Santa Barbara : 1199.33.01026 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Torrance : 1199.33.01007 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Danbury : 1199.33.01006 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Stamford : 1199.33.01017 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Washington : Georgetown University

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Clearwater : Bay Area Chest Physicians

A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)

Jacksonville : Investigational Site Number 840009

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Jacksonville : Investigational Site Number 840011

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Tampa : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Stockbridge : Arthritis Research & Treatment Center Rheumatology

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Chicago : Investigational Site Number 840006

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Joliet : Investigational Site Number 840004

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Maywood : Investigational Site Number 840005

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Michigan City : LaPorte County Institute for Clinical Research, Inc

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Wichita : 1199.33.01023 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Wichita : Investigational Site Number 840002

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Lexington : University of Kentucky

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Louisville : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Louisville : Kentuckiana Pulmonary Associates

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl

Shreveport : LSU Health Sciences Center

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Boston : Brigham & Women's Hospital -Pulmonary and Critical Care Medicine

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl

Minneapolis : 1199.33.01005 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Minneapolis : Investigational Site Number 840003

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

St. Louis : Washington University School of Medicine

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl

Lebanon : 1199.33.01027 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

New Brunswick : UMDNJ-RWJ Medical School

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Newark : University of Medicine and Dentistry of New Jersey

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl

Summit : Pulmonary & Allergy Associates, P.A.

A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)

Summit : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Albany : 1199.33.01041 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Jamaica : 1199.33.01010 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Lake Success : North Shore-LIJ Health System

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

New York : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

New York : Investigational Site Number 840013

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Chapel Hill : UNC-Chapel Hill

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

Chapel Hill : UNC Hospitals

Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability

Durham : Duke University Medical Center

Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability

Durham : Duke University Medical Center

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

Durham : Novartis Investigative Site

Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Cincinnati : The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl

Cincinnati : Investigational Site Number 840014

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Cleveland : Cleveland Clinic

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl

Cleveland : Clevleand Clinic Foundation

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Columbus : Ohio State University, Martha Morehouse Medical Plaza

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl

View More »

Toledo : University of Toledo College of Medicine

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Portland : 1199.33.01004 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Pittsburgh : 1199.33.01032 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Pittsburgh : Allegheny General Hospital

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl

Pittsburgh : University of Pittsburgh

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Charleston : 1199.33.01024 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Charleston : Investigational Site Number 840010

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Shelbyville : 1199.33.01016 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Houston : Investigational Site Number 840012

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Longview : 1199.33.01019 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

McKinney : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

McKinney : 1199.33.01021 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

San Antonio : 1199.33.01001 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Salt Lake City : University of Utah

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl

Lynchburg : 1199.33.01002 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Milwaukee : Aurora St. Luke's Medical Center

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl

Camperdown : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Camperdown : 1199.33.61001 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Chermside : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Chermside : The Prince Charles Hospital

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Concord : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

View More »

Concord : 1199.33.61002 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Darlinghurst : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Frankston : 1199.33.61005 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Melbourne : 1199.33.61004 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

New Lambton : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Prahran : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Toorak Gardens : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Woodville South : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Bruxelles : 1199.33.32004 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Leuven : 1199.33.32001 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Leuven : Investigational Site Number 056001

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Yvoir : 1199.33.32002 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Edmonton : Investigational Site Number 124003

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Hamilton : Investigational Site Number 124001

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Vancouver : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Vancouver : Investigational Site Number 124002

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Windsor : Research Site

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Concepción : Investigational Site Number 152004

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Santiago : Investigational Site Number 152001

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Santiago : Investigational Site Number 152002

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Santiago : Investigational Site Number 152003

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Beijing : Peking Union Medical College Hospital

Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)

Vantaa : 1199.33.35802 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

BOBIGNY Cedex : 1199.33.33002 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Lille Cedex : 1199.33.33009 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Lyon cedex : 1199.33.33011 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Marseille : 1199.33.33013 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Montpellier Cedex 5 : 1199.33.33008 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

View More »

Nice Cedex 1 : 1199.33.33003 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Paris : 1199.33.33006 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Paris Cedex 18 : 1199.33.33001 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Reims Cedex : 1199.33.33007 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Rennes Cedex 9 : 1199.33.33004 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Toulouse Cedex 9 : 1199.33.33012 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Bad Nauheim : Kerckhoff-Klinik gGmbH

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Bamberg : 1199.33.49008 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Berlin : 1199.33.49009 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Berlin : Charité-Campus Mitte

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Bochum : Klinik III für Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin, Berufs¬genossen-schaftliches Universitätsklinikum Bergmannsheil GmbH

Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (IPF)

View More »

Coswig : 1199.33.49010 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Donaustauf : 1199.33.49005 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Erlangen : Universitätsklinikum Erlangen

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Essen : 1199.33.49001 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Frankfurt : Klinikum der Johann Wolfgang Goethe Universität

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Freiburg/Breisgau : 1199.33.49002 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Hannover : Klinik für Pneumologie, Medizinische Hochschule Hannover

Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (IPF)

Heidelberg : 1199.33.49007 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Heidelberg : Pneumologie und Beatmungsmedizin, Thoraxklinik,Universitätsklinikum

Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (IPF)

Herne : Rheumazentrum Ruhrgebiet St. Josefs-Krankenhaus

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Immenhausen : 1199.33.49013 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Leipzig : Abteilung für Pneumologie Department Innere Medizin, Neurologie und Dermatologie Universitätsklinikum Leipzig AöR

Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (IPF)

Mainz : 1199.33.49004 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

München : 1199.33.49011 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Ulm : Universitätsklinikum Ulm

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Athens : 1199.33.30005 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Heraklion : 1199.33.30001 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Forli' : 1199.33.39008 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Genova : Azienda Ospedaliera Universitaria S. Martinodi Genova

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Milano : Fondazione IRCCS-Ca' Granda-Ospedale Maggiore Policlinico

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Modena : 1199.33.39001 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Monza : 1199.33.39007 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

View More »

Napoli : 1199.33.39011 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Pisa : 1199.33.39006A Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Pisa : 1199.33.39006B Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Pisa : Azienda Ospedaliera Universitaria Pisana

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Roma : 1199.33.39010 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Bucheon : 1199.33.82002 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Incheon : 1199.33.82004 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Seoul : 1199.33.82006 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Seoul : 1199.33.82007 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Seoul : 1199.33.82001 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

View More »

Seoul : 1199.33.82003 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Mexico City : Investigational Site Number 484003

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Monterrey : Investigational Site Number 484002

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Amsterdam : 1199.33.31002 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Nieuwegein : 1199.33.31001 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Rotterdam : 1199.33.31003 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Coimbra : 1199.33.35105 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Lisboa : 1199.33.35102 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Lisboa : 1199.33.35103 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Porto : 1199.33.35101 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Doha : Hamad Medical Corporation

Blood Collection From Individuals With Lung Disease for Genetic Studies (Qatar)

Barcelona : 1199.33.34004 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Barcelona : 1199.33.34003 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Barcelona : Investigational Site Number 724002

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Barcelona : Investigational Site Number 724001

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

L´Hospitalet de Llobregat : 1199.33.34005 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

View More »

Madrid : Hospital Universitario 12 de Octubre

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Madrid : Hospital Universitario Gregorio Marañón

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Santiago de Compostela : Complejo Hospitalario de Santiago

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Sevilla : 1199.33.34008 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Valencia : Hospital Universitario Dr. Peset

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Basel : Felix-Platter Spital

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Aberdeen : 1199.33.44006 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Birmingham : 1199.33.44003 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Birmingham : 1199.33.44005 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Leeds : Leeds Institute of Molecular Medicine University of Leeds-Chapel Allerton Hospital

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Liverpool : 1199.33.44004 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

View More »

London : 1199.33.44002 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

London : Royal Brompton Hospital

IPF Drug Deposition Study

London : Royal Brompton Hospital

Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study

London : Centre for Rheumatology and Connective Tissue Diseases

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Nottingham : Nottingham University Hospitals NHS Trust

Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England)

Oxford : 1199.33.44008 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Westbury on Trym : 1199.33.44001 Boehringer Ingelheim Investigational Site

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis